Skip to main content
SpringerLink
Log in

Global Epidemiology of Acute Viral Hepatitis A–E

  • Chapter
  • First Online:
Viral Hepatitis: Acute Hepatitis

Abstract

Worldwide, viral hepatitides are caused by five well-characterized hepatotropic viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus (HDV), and hepatitis E virus (HEV). Their epidemiology as well as their pathogenesis have been studied in great detail. Further, the structure and genetic organization of their DNA or RNA genome including the viral life cycle have been elucidated. These discoveries have been successfully translated into important clinical applications, such as the specific diagnosis, therapy, and prevention of the associated liver diseases, including acute or fulminant hepatitis, as well as the long-term sequelae of chronic hepatitis, including liver cirrhosis and hepatocellular carcinoma (HCC).

The prevalence of viral hepatitis A–E shows distinct geographic differences. The global burden of these infections (prevalence, incidence, cause-specific death, disability-adjusted life years, and years of life lost) has recently been analyzed in seminal studies. During the coming decade(s) we expect to further improve our ability to prevent and to effectively treat viral hepatitis A–E, resulting in the control or even elimination of these global infections and of their associated morbidities and mortalities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. 1973;182:1026–8.

    Article  CAS  Google Scholar 

  2. Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology. 2006;43:S164–72.

    Article  CAS  Google Scholar 

  3. Blumberg BS, Alter HJ, Visnich S. A “New” Antigen in Leukemia Sera. JAMA. 1965;191:541–6.

    Article  CAS  Google Scholar 

  4. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66:924–31.

    Article  CAS  Google Scholar 

  5. Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A. 1968;60:814–21.

    Article  CAS  Google Scholar 

  6. Prince AM. Relation of Australia and SH antigens. Lancet. 1968;2:462–3.

    Article  CAS  Google Scholar 

  7. Prince AM, Hargrove RL, Szmuness W, Cherubin CE, Fontana VJ, Jeffries GH. Immunologic distinction between infectious and serum hepatitis. N Engl J Med. 1970;282:987–91.

    Article  CAS  Google Scholar 

  8. Krugman S, Giles JP. Viral hepatitis. New light on an old disease. JAMA. 1970;212:1019–29.

    Article  CAS  Google Scholar 

  9. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A. 1994;91:8239–43.

    Article  CAS  Google Scholar 

  10. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62.

    Article  CAS  Google Scholar 

  11. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362–4.

    Article  CAS  Google Scholar 

  12. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494–500.

    Article  CAS  Google Scholar 

  13. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.

    Article  CAS  Google Scholar 

  14. Centers for Disease C, Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62:362–5.

    Google Scholar 

  15. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–35.

    Article  Google Scholar 

  16. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997–1003.

    Article  CAS  Google Scholar 

  17. Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A. 1980;77:6124–8.

    Article  CAS  Google Scholar 

  18. Gupta DN, Smetana HF. The histopathology of viral hepatitis as seen in the Delhi epidemic (1955–56). Indian J Med Res. 1957;45:101–13.

    CAS  PubMed  Google Scholar 

  19. Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, Poleschuk VF. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20:23–31.

    Article  CAS  Google Scholar 

  20. Kane MA, Bradley DW, Shrestha SM, Maynard JE, Cook EH, Mishra RP, Joshi DD. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA. 1984;252:3140–5.

    Article  CAS  Google Scholar 

  21. Krawczynski K, Bradley DW. Enterically transmitted non-A, non-B hepatitis: identification of virus-associated antigen in experimentally infected cynomolgus macaques. J Infect Dis. 1989;159:1042–9.

    Article  CAS  Google Scholar 

  22. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367:1237–44.

    Article  CAS  Google Scholar 

  23. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, Dalton HR. Hepatitis E. Lancet. 2012;379:2477–88.

    Article  Google Scholar 

  24. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–7.

    Article  Google Scholar 

  25. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev. 2006;28:101–11.

    Article  Google Scholar 

  26. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005;294:194–201.

    Article  CAS  Google Scholar 

  27. Advisory Committee on Immunization P, Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2006;55:1–23.

    Google Scholar 

  28. Wasley A, Grytdal S, Gallagher K. Centers for disease C, prevention. Surveillance for acute viral hepatitis—United States, 2006. MMWR Surveill Summ. 2008;57:1–24.

    PubMed  Google Scholar 

  29. Daniels D, Grytdal S, Wasley A, Centers for Disease C, Prevention. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ. 2009;58:1–27.

    PubMed  Google Scholar 

  30. Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, Sweet K, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005–2007. Arch Intern Med. 2010;170:1811–8.

    Article  Google Scholar 

  31. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.

    Article  CAS  Google Scholar 

  32. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.

    Article  CAS  Google Scholar 

  33. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202:192–201.

    Article  Google Scholar 

  34. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–8.

    Article  Google Scholar 

  35. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55:1–33; quiz CE31–34.

    PubMed  Google Scholar 

  36. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.

    Article  Google Scholar 

  37. Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8(Suppl):S10–4; discussion S21–13.

    Article  Google Scholar 

  38. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.

    Article  Google Scholar 

  39. Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, Sagnelli E, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000;32:824–7.

    Article  CAS  Google Scholar 

  40. Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, Vergani D, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008;80:277–82.

    Article  Google Scholar 

  41. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection—not a vanishing disease in Europe! Hepatology. 2007;45:1331–2; author reply 1332–1333

    Article  Google Scholar 

  42. Borresen ML, Olsen OR, Ladefoged K, McMahon BJ, Hjuler T, Panum I, Simonetti J, et al. Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat. 2010;17:162–70.

    Article  CAS  Google Scholar 

  43. Tsatsralt-Od B, Takahashi M, Endo K, Buyankhuu O, Baatarkhuu O, Nishizawa T, Okamoto H. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia. J Med Virol. 2006;78:542–50.

    Article  CAS  Google Scholar 

  44. Emerson SU, Purcell RH. Running like water—the omnipresence of hepatitis E. N Engl J Med. 2004;351:2367–8.

    Article  CAS  Google Scholar 

  45. Stramer SL, Moritz ED, Foster GA, Ong E, Linnen JM, Hogema BM, Mak M, et al. Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors. Transfusion. 2016;56:481–8.

    Article  CAS  Google Scholar 

  46. Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE. Epidemiology of hepatitis E virus in the United States: results from the third national health and nutrition examination survey, 1988–1994. J Infect Dis. 2009;200:48–56.

    Article  Google Scholar 

  47. Teshale EH, Denniston MM, Drobeniuc J, Kamili S, Teo CG, Holmberg SD. Decline in hepatitis E virus antibody prevalence in the United States from 1988–1994 to 2009–2010. J Infect Dis. 2015;211:366–73.

    Article  CAS  Google Scholar 

  48. Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, Myint KS, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356:895–903.

    Article  CAS  Google Scholar 

  49. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376:895–902.

    Article  CAS  Google Scholar 

  50. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.

    Article  CAS  Google Scholar 

  51. Peron JM, Abravanel F, Guillaume M, Gerolami R, Nana J, Anty R, Pariente A, et al. Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. Liver Int. 2016;36:328–33.

    Article  CAS  Google Scholar 

  52. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–128.

    Article  Google Scholar 

  53. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2197–223.

    Article  Google Scholar 

  54. Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet:2015.

    Google Scholar 

  55. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1151–210.

    Article  Google Scholar 

  56. DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1260–344.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital Freiburg, Freiburg im Breisgau, Germany

    Hubert E. Blum

Authors
  1. Hubert E. Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert E. Blum .

Editor information

Editors and Affiliations

  1. Cerrahasa Medical School, Istanbul University Cerrahasa Medical School, Istanbul, Turkey

    Resat Ozaras

  2. University Medical Center Utrecht, GA Utrecht, Utrecht, The Netherlands

    Joop E. Arends

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Blum, H.E. (2019). Global Epidemiology of Acute Viral Hepatitis A–E. In: Ozaras, R., Arends, J. (eds) Viral Hepatitis: Acute Hepatitis. Springer, Cham. https://doi.org/10.1007/978-3-030-03535-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03535-8_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03534-1

  • Online ISBN: 978-3-030-03535-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation